Sign In
Buy MDWD
$13.73
-0.0300 (-0.218%)
At Close: Jun 03, 2026
MediWound: Adjusting My Strategy After NexoBrid CRL
02:11pm, Wednesday, 28'th Jul 2021
MediWound: Adjusting My Strategy After NexoBrid CRL
MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer
09:36am, Monday, 26'th Jul 2021
MediWound Ltd (NASDAQ: MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated Phase 2 trial of MW005 in non-melanoma s
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
07:00am, Monday, 26'th Jul 2021
Data Expected End of 2021
MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients
08:18am, Tuesday, 20'th Jul 2021
MediWound Ltd (NASDAQ: MDWD) has announced topline results from Phase 3 pediatric study with NexoBrid to treat severe thermal burns. The 145-subject study met its three primary endpoints.
MDWD Stock Increases Over 15% Pre-Market: Why It Happened
08:13am, Tuesday, 20'th Jul 2021
The stock price of Mediwound Ltd (NASDAQ: MDWD) increased by over 15% pre-market. This is why it happened.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
10:45am, Sunday, 18'th Jul 2021
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
10:08pm, Monday, 05'th Jul 2021
New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD
09:15pm, Tuesday, 29'th Jun 2021
NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. ("MediWound" or the "Company") (NASDAQ: MDWD).
Why Shares Of MediWound And Vericel Fell On Tuesday
01:10pm, Tuesday, 29'th Jun 2021
Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid
FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
09:23am, Tuesday, 29'th Jun 2021
Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar r
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application
08:45am, Tuesday, 29'th Jun 2021
Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therapy Company Remains Committed to Working with FDA Toward a Potential Approval for this Important Therap
Best Penny Stocks To Buy Now? 7 To Watch This Week
01:09pm, Sunday, 20'th Jun 2021
What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
04:30pm, Wednesday, 09'th Jun 2021
Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021 Interim Assessment Expected by end of July 2021 and Completion of Enrollment by Year-End 2021
MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript
03:14pm, Saturday, 08'th May 2021
MediWound Ltd (MDWD) CEO Sharon Malka on Q1 2021 Results - Earnings Call Transcript
